| 2.31 -0.05 (-2.12%) | 10-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.08  |
1-year : | 3.5 |
| Resists | First : | 2.63 |
Second : | 3 |
| Pivot price | 2.21 | |||
| Supports | First : | 2.04 | Second : | 1.7 |
| MAs | MA(5) : | 2.22 |
MA(20) : | 2.31 |
| MA(100) : | 5.02 |
MA(250) : | 13.34 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 42.7 |
D(3) : | 27.1 |
| RSI | RSI(14): 41.5 |
|||
| 52-week | High : | 53.2 | Low : | 2.04 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ XAIR ] has closed below upper band by 23.3%. Bollinger Bands are 86.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 29 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.43 - 2.44 | 2.44 - 2.45 |
| Low: | 2.27 - 2.28 | 2.28 - 2.29 |
| Close: | 2.29 - 2.31 | 2.31 - 2.33 |
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
Thu, 29 Oct 2026
Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2026 - Yahoo Finance
Sat, 24 Oct 2026
Beyond Air, Inc. Estimates – NASDAQ:XAIR - TradingView
Wed, 21 Oct 2026
A 14.8% stake falls below the 10% ownership threshold at Beyond Air (XAIR). - Stock Titan
Wed, 14 Oct 2026
At $2.21 a share, Beyond Air (XAIR) ten percent owner Lin Yi-Chien buys 2,607 shares. - Stock Titan
Wed, 14 Oct 2026
Beyond Air director Lin Yi-Chien buys $5,761 in company stock - Investing.com
Thu, 08 Oct 2026
Beyond Air (XAIR) Reports 27% Revenue Growth in Q3 2026 Amid Ong - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 20.8 (%) |
| Held by Institutions | 7.9 (%) |
| Shares Short | 63 (K) |
| Shares Short P.Month | 73 (K) |
| EPS | -63.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.69 |
| Profit Margin | 0 % |
| Operating Margin | -374 % |
| Return on Assets (ttm) | -57.5 % |
| Return on Equity (ttm) | -519.6 % |
| Qtrly Rev. Growth | 0.5 % |
| Gross Profit (p.s.) | 0.32 |
| Sales Per Share | 7.81 |
| EBITDA (p.s.) | -25.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -0.04 |
| PEG Ratio | 0 |
| Price to Book value | 0.85 |
| Price to Sales | 0.29 |
| Price to Cash Flow | -0.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|